Zymeworks BC Inc ZYME Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$29.63 up $0.90, 3.11% at close Nov 6
Last close · Previous close $28.74
- Market cap
- $2.16BAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$2.02Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$29.63up $0.90, 3.11%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$28.74Nov 5
- Volume907.97KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.40MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $16.57 to $31.49; now $29.63
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ZYME beat the S&P 500 in 5 of 6 periods.
| Period | ZYME and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ZYME: up 15.5% S&P 500: down 5.6% | ZYME beat the S&P 500 by 21.1 percentage points Beat |
| 3M | ZYME: up 28.1% S&P 500: down 4.1% | ZYME beat the S&P 500 by 32.2 percentage points Beat |
| YTD | ZYME: up 12.5% S&P 500: up 8.7% | ZYME beat the S&P 500 by 3.8 percentage points Beat |
| 1Y | ZYME: up 65.5% S&P 500: up 10.9% | ZYME beat the S&P 500 by 54.6 percentage points Beat |
| Long term | ||
| 3Y | ZYME: up 307.0% S&P 500: up 75.0% +59.7% vs +20.5% a year | ZYME beat the S&P 500 by 232.0 percentage points Beat |
| 5Y | ZYME: up 28.3% S&P 500: up 67.8% +5.1% vs +10.9% a year | ZYME trailed the S&P 500 by 39.5 percentage points Trailed |
$10,000 invested in ZYME 5 years ago (Nov 5, 2021) would be worth about $12,827 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
ZYME beat the S&P 500 in 5 of 6 periods.
| Period | ZYME and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ZYME: up 15.5% S&P 500: down 5.6% | ZYME beat the S&P 500 by 21.1 percentage points Beat |
| 3M | ZYME: up 28.1% S&P 500: down 4.3% | ZYME beat the S&P 500 by 32.4 percentage points Beat |
| YTD | ZYME: up 12.5% S&P 500: up 7.8% | ZYME beat the S&P 500 by 4.7 percentage points Beat |
| 1Y | ZYME: up 65.5% S&P 500: up 9.7% | ZYME beat the S&P 500 by 55.8 percentage points Beat |
| Long term | ||
| 3Y | ZYME: up 307.0% S&P 500: up 68.8% +59.7% vs +19.1% a year | ZYME beat the S&P 500 by 238.2 percentage points Beat |
| 5Y | ZYME: up 28.3% S&P 500: up 56.9% +5.1% vs +9.4% a year | ZYME trailed the S&P 500 by 28.6 percentage points Trailed |
$10,000 invested in ZYME 5 years ago (Nov 5, 2021) would be worth about $12,827 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$56.81
Closing high on . Now 47.8% below that record.
Split-adjusted daily closes since Apr 28, 2017.
Stock splits
ZYME hasn’t split since its price history begins in 2017.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$2.02 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. When ZYME was profitable over the past five years, its P/E ranged from 2.0× to 5.1×, with a median of 3.1×. How to read P/E
Other valuation measures
- 58.3×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 26.9×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −5.57%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $2.16BAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own ZYME DCF in Excel. Value Zymeworks BC with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $37.13Mdown 69.8%
- Net income
- −$149.99M
- Diluted EPS
- −$2.02
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $16.00M | −$29.85M | −$0.39 |
| Q4 FY24 (Dec 31, 2024) | $31.03M | −$23.51M | −$0.32 |
| Q1 FY25 (Mar 31, 2025) | $27.11M | −$22.64M | −$0.30 |
| Q2 FY25 (Jun 30, 2025) | $48.73M | $2.32M | $0.03 |
| Q3 FY25 (Sep 30, 2025) | $27.61M | −$19.60M | −$0.26 |
| Q4 FY25 (Dec 31, 2025) | $2.52M | −$41.21M | −$0.55 |
| Q1 FY26 (Mar 31, 2026) | $2.41M | −$44.16M | −$0.59 |
| Q2 FY26 (Jun 30, 2026) | $4.59M | −$45.02M | −$0.62 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $26.68M | −$211.84M | −$4.61 |
| FY22 (Dec 31, 2022) | $412.48M | $124.34M | $1.90 |
| FY23 (Dec 31, 2023) | $76.01M | −$118.67M | −$1.72 |
| FY24 (Dec 31, 2024) | $76.30M | −$122.70M | −$1.62 |
| FY25 (Dec 31, 2025) | $105.97M | −$81.13M | −$1.08 |
Margins
- Gross 100.0%
- Operating −419.0%
- Net −404.0%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$120.54MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$119.34MLast 12 months
- Capital spending$1.21MLast 12 months
- −324.7%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $136.97MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$136.97MLast 12 months
Balance sheet
- $322.48MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$268.64MAs of Jun 30, 2026
- Net cash$53.84MAs of Jun 30, 2026
- 6.32As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 3.34As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 1 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −72.1%Last 12 months
Over the last 12 months, Zymeworks BC lost money: its net loss was 72.1% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −37.1%Last 12 months
Over the last 12 months, Zymeworks BC’s net loss was 37.1% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Zymeworks BC Inc
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera ® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Delaware, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ZYME news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ZYME stock FAQ
What is ZYME stock’s price today?
Zymeworks BC (ZYME) traded at $29.63 at the close on , up $0.90 (3.11%) from the previous close of $28.74. Over the past 52 weeks it has traded between $16.57 and $31.49.
If you invested $1,000 in ZYME 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ZYME on would be worth about $1,283 at the close on , a total return of +28.3%. The same $1,000 would be worth $1,655 if invested one year ago. Past performance doesn’t predict future returns.
What is Zymeworks BC’s market cap?
Zymeworks BC’s market capitalization is about $2.2 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $29.63 (how market cap works). Zymeworks BC reported 73.02M shares outstanding at the end of its latest quarter ().
What is ZYME’s P/E ratio?
ZYME’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$2.02). When it was profitable over the past five years, its P/E ranged from 2.0 to 5.1.
How much revenue does Zymeworks BC make?
Zymeworks BC reported $37.1 million of revenue over the four quarters to , down 69.8% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $4.6 million, down 90.6% from a year earlier.
Is Zymeworks BC profitable?
Not over the four quarters to . Zymeworks BC reported a net loss of $150.0 million across those four quarters on $37.1 million of revenue.
What are ZYME’s earnings per share?
ZYME’s diluted earnings per share were −$2.02 over the four quarters to , compared with −$0.98 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.62 per share, against $0.03 a year earlier (how EPS works).
Does ZYME pay a dividend?
Zymeworks BC hasn’t paid a dividend in the last twelve months.
What is ZYME’s 52-week high and low?
Over the past 52 weeks ZYME has traded as low as $16.57 and as high as $31.49. At $29.63 at the close on , it is 5.9% below that high and 78.9% above the low.
What is ZYME’s all-time high?
ZYME’s highest closing price was $56.81 on , adjusted for stock splits. At $29.63 at the close on , it is 47.8% below that record.
Has ZYME stock ever split?
No. ZYME hasn’t split since its price history begins in 2017.
How has ZYME stock performed?
Including dividends and measured to the close on , ZYME has returned +12.5% so far this year and +65.5% over the past year, and +28.3% over five years (+5.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Zymeworks BC in?
Zymeworks BC is in the Healthcare sector and the Biotechnology industry, and is headquartered in Delaware, USA.
What exchange does ZYME trade on?
Zymeworks BC trades on the Nasdaq under the ticker symbol ZYME. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.